chrisvoncsefalvay/vaers-outcomes huggingface dataset:
two individuals received the Moderna vaccine dose #2 at day 21; 2 of these 72 individuals who received the expired vaccine; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by an other health care professional and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (two individuals received the Moderna vaccine dose #2 at day 21) and EXPIRED PRODUCT ADMINISTERED (2 of these 72 individuals who received the expired vaccine) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     No Medical History information was reported.   On 11-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Jul-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (two individuals received the Moderna vaccine dose #2 at day 21) and EXPIRED PRODUCT ADMINISTERED (2 of these 72 individuals who received the expired vaccine). On 02-Jul-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (two individuals received the Moderna vaccine dose #2 at day 21) and EXPIRED PRODUCT ADMINISTERED (2 of these 72 individuals who received the expired vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  Treatment information was not provided.
On Thursday I had to make a dangerous pilgrimage to a rough section with addicts and gangs and wait in a line standing up for hours but in the school I got a strong jab of what I hope was my second dose of Moderna.Yesterday?s COVID fatigue was a tsunami, reminding me of how my immune system will feel when facing destruction and death. It reminded me a bit of getting up after abdominal surgery, high altitude pulmonary edema, severe hypothermia because of the chills, and herpes without the painful rash because I couldn?t do any exercise and I was extremely depressed. After a long sleep and a huge brunch, I feel better so my immune system has kicked in. I am even more for the vaccine because this has given me a hint of what COVID could have done to me as it killed ten of my colleagues my age in great shape.
7MAR wheezing, itchy eyes, rhinitis, not feeling well allerg rxn;
Pt had inconsolable crying after shots in the PM. Tylenol given at 12 midnight and at 5am the following day. Pt unable to nurse for 1 whole day. Pt received in 24 hours.
Severe migraine overnight, difficulty sleeping.  Slight headache for several days after.  Slightly elevated temperature overnight.  Inconsolable crying and sadness overnight.  Depression symptoms worsening and continuing to be worse than before vaccination.
I had a red rash about the size of a tennis ball by about Day 9 or day 10; itched; burned; was somewhat painful; I had a red rash about the size of a tennis ball by about Day 9 or day 10; It was firm; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (I had a red rash about the size of a tennis ball by about Day 9 or day 10), RASH PRURITIC (itched), BURNING SENSATION (burned), RASH (was somewhat painful) and SWELLING (I had a red rash about the size of a tennis ball by about Day 9 or day 10) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In February 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH ERYTHEMATOUS (I had a red rash about the size of a tennis ball by about Day 9 or day 10), RASH PRURITIC (itched), BURNING SENSATION (burned), RASH (was somewhat painful), SWELLING (I had a red rash about the size of a tennis ball by about Day 9 or day 10) and INDURATION (It was firm). At the time of the report, RASH ERYTHEMATOUS (I had a red rash about the size of a tennis ball by about Day 9 or day 10), RASH PRURITIC (itched), BURNING SENSATION (burned), RASH (was somewhat painful), SWELLING (I had a red rash about the size of a tennis ball by about Day 9 or day 10) and INDURATION (It was firm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.  Treatment information was not provided.
Child received 0.3ml adult Pfizer in left arm. Patient came with aunt  and waited in observation for 15mins. No symptoms noted. Site Lead spoke to mother 12/31/2021 at 1624 to make her aware of incident. All questions and concerns addressed.
Patient had a seizure approximately 10 minutes after vaccination.  She was seated and her daughter was with her.  Daughter reported seizures are common with her mom but this one seemed to be longer in duration than normal.
Bodyaches and chills and major back pain  x 2 days and still having back pain  since first dose of vaccination and started a hand rash on 1/14/2020
SEVERE ABDOMINAL PAIN; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, batch number and expiry date were not reported) dose, start therapy date were not reported for covid-19 prophylaxis. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, the patient experienced severe abdominal pain. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of severe abdominal pain was not reported. This report was non-serious.
shingles/ unbelievable painful; This case was reported by a consumer via interactive digital media and described the occurrence of shingles in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced shingles. On an unknown date, the outcome of the shingles was recovered/resolved.   It was unknown if the reporter considered the shingles to be related to Shingles vaccine.  Additional details were provided as follows: The patient self-reported this case. The age at vaccination was not reported.  The patient reported that he/she got one shingles vaccine shot then got the shingles for 6 month and it was unbelievable painful. The follow-up would not be possible as no contact details were available.
About 5 hours after vaccination, unusual ?stingy? headache and tiredness, some malaise after nap. Symptoms lessened, then disappeared during morning of next day. About 30 hours after vaccination, hot flashes (no fever), chills, tired, but jittery with difficulty sleeping, dizzy, head felt ?weird?, - mostly diminished in morning. About 48 hours after vaccination, headache and tiredness returned -still no fever. Very little soreness in arm over the past two days since injection.
Three days after vaccination I went to see the doctor because I started itching and had redness all over but mainly in areas around joints, and it would not stop. He gave me a shot of cortisone. I was also prescribed a series of steroids as well as a scabies cream to apply to my skin. I got better 24 hours later. Then, on the highway, I went to the hospital emergency room because I was hurting all over, especially my feet. I was diagnosed with Erythema Multiforme. They told me that since I was still on prednisone, to increase fluids and rest. I am still experiencing these symptoms but they are much less acute.
This child had a fever of 103 F axillary approximately 12 hours after his shots; duration approximately 36 hours developed vomiting 2 days later with loose diarrheal stools 24 hours after vomiting. Diagnosed with URI and RADM on 02/02/01.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 45-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 20Feb2021 as dose 1, single (Batch/Lot number: unknown), in left arm, on 13Mar2021 as dose 2, single (Batch/Lot number: unknown), in left arm and on 10Oct2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 44 years, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Unknown results, notes: COVID 19 Treatment; (10Jun2022) Negative; (11Jun2022) Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical course: Other medication in 2weeks was reported as no. Antiviral details: product: COVID 19 Treatment, Brand: Paxlovid, Treatment start date: 02Jun2022, Treatment stop date: 07Jun2022, Indication: Treatment of COVID-19, Adverse event: Paxlovid rebound. Symptoms returned 3 days after treatment ended. Rapid antigen at home test returned a negative result Friday 10Jun2022 and then changed back to positive after symptoms returned one day post symptoms on Saturday 11Jun2022.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This spontaneous report as received from a healthcare worker refers to a 4 month old patient of unknown gender. The patient's relevant medical history, current conditions and concomitant medications were not reported. On 12-OCT-2015 the patient was vaccinated with improperly stored ROTATEQ (dosing details were not reported) lot # L008053, with an expiry date of 30-NOV-2016, orally (incorrect product storage). The vaccine was administered at public health clinic or hospital with public funds. No adverse effects were reported. There was no product quality complaint involved. This is one of the several reports received from the same reporter. Additional information has been requested.
My wife had higher IL6 response with her 2nd dose of the Moderna Covid-19 vaccine; This spontaneous case was reported by a consumer and describes the occurrence of INTERLEUKIN LEVEL INCREASED (My wife had higher IL6 response with her 2nd dose of the Moderna Covid-19 vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient has no medical history reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-May-2021, the patient experienced INTERLEUKIN LEVEL INCREASED (My wife had higher IL6 response with her 2nd dose of the Moderna Covid-19 vaccine). At the time of the report, INTERLEUKIN LEVEL INCREASED (My wife had higher IL6 response with her 2nd dose of the Moderna Covid-19 vaccine) outcome was unknown.            Concomitant medication was not reported. Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 14-Jun-2021: NNI
Dose given may have been 1 hour and 15 minutes later than the 6 hour limit of use of a Moderna open vial of vaccine.
Nausea all day for one week followed by nausea on and off (usually in the mornings and at night) for an additional three weeks and ongoing
Four hours after my 3rd dose I had a fever; vomiting; nausea and I stay in bed all day. I couple weeks after I had chest pain. In February of 2022 I had eye problems. I went to the doctor and they said I might have optic neuritis. Now I take medications to treat it.
A subject , diagnosed with bladder cancer with resection on March 2002, received an initial series of Tice BCG approximately.  May-July 2002 with no problems reported.  A second series of 6 weekly instillations was started approximately 09/12/2002, with the 2nd instillation on 09/17/2002.  Following each of the 2 recent instillation, the subject experienced a significant headache.  Also reported was a mild burning discomfort with voiding.  The 3rd instillation was withheld due to urinary tract infection.  Treatment headache: Tylenol.  Treatment: urinary tract infection: Keflex (oral), started 09/26/2002.
Reported a strange taste in her mouth that started a few days after receiving the vaccine.  It continues as of yesterday (almost 3 weeks after receiving first dose).; This is a spontaneous report from a non-contactable consumer. This 76-year-old female consumer reported that.  A 76-years-old non pregnant female consumer received bnt162b2 (COVID 19, brand Pfizer, Formulation: Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 28Jan2021 as dose 1, single for covid-19 immunisation (age at Vaccination was 76). The patient's medical history and concomitant medications were not reported. The patient experienced a strange taste in her mouth that started a few days after receiving the vaccine. Onset date of event was reported as 31Jan2021. It continued almost 3 weeks after receiving first dose till 1 day before the day of report. Facility type of vaccine was reported as hospital. Other vaccine received in four weeks was reported as unknown. Patient was not Covid prior vaccination and not tested Covid post vaccination. The reason for lot unknown was reported as not available or provided to reporter at the time of report completion. The patient had not received treatment for the reported event. Outcome of event was report as unknown.  No follow-up attempts are possible and information about lot/batch number cannot be obtained.
Covid arm- red swelling on the injection site; Covid arm- red swelling on the injection; Chills; Tiredness; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (Chills), FATIGUE (Tiredness), INJECTION SITE SWELLING (Covid arm- red swelling on the injection site) and INJECTION SITE ERYTHEMA (Covid arm- red swelling on the injection) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (The patient's medical history was not provided.).    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Feb-2021, the patient experienced CHILLS (Chills) and FATIGUE (Tiredness). On an unknown date, the patient experienced INJECTION SITE SWELLING (Covid arm- red swelling on the injection site) and INJECTION SITE ERYTHEMA (Covid arm- red swelling on the injection). At the time of the report, CHILLS (Chills), FATIGUE (Tiredness), INJECTION SITE SWELLING (Covid arm- red swelling on the injection site) and INJECTION SITE ERYTHEMA (Covid arm- red swelling on the injection) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information was provided as Tylenol. Relevant concomitant medications were not reported.      Reporter did not allow further contact
pregnant female received expired Fluzone with no reported adverse event.; pregnant female received expired Fluzone with no reported adverse event.; Initial information received on 10-Feb-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 21 years old female patient who was exposed to vaccine INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QIV] in and pregnant female received expired fluzone with no reported adverse event at unknown gestation period<<the gestation period at onset and gestation period at exposure data needs to be populated, if available.  The date of last menstrual period was not reported. The estimated due date was not reported. The actual date of delivery was not reported. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. The patient had unknown previous pregnancy/ies.  On an unknown date of February 2022, the patient received a  dose of suspect INFLUENZA QUADRIVAL A-B VACCINE Suspension for injection (lot UT7065MA and expiration date: 30-Jun-2021) once via unknown route in unknown administration site a prophylactic vaccination.  In FEB-2022, the patient developed a non-serious event "pregnant female received expired fluzone with no reported adverse event" (exposure during pregnancy)(expired product administered) (latency: same day) following the administration of INFLUENZA QUADRIVAL A-B VACCINE.  Action taken with QUADRIVALENT INFLUENZA VACCINE (FLUZONE QIV) was not applicable.  It was not reported if the patient received a corrective treatment for the events (pregnant female received expired Fluzone with no reported adverse event., pregnant female received expired Fluzone with no reported adverse event.).  At time of reporting, the outcome was Unknown for the event pregnant female received expired fluzone with no reported adverse event. and was Unknown for the event pregnant female received expired fluzone with no reported adverse event.. Additionally, at time of reporting, the outcome of the pregnancy is unknown.
Mom called the morning of 06/02/20 and stated that patient's right thigh was the size of a tennis ball with redness and swelling and the area was tender to touch. Mom was advised to apply cold compresses and give OTC Benadryl for the next 24 hours and call back if symptoms worsened. Mom called back today 06/03/20 stating that symptoms are worse and patient is limping. provider saw patient with the following description to the rt thigh (Area of erythema, mild tenderness, no drainage, not warm. ) Pt was prescribed the following medications and treatment plan:1) orapred 1 tsp once a day for three days 2) clindamycin 1 tsp twice a day for one week 3) 7ml of Benadryl at bedtime only 4) continue to use tylenol if needed for pain, 5) call on Friday 06/05/2020 with update
Soreness in left arm; Fatigue/needed to sleep and rest; lethargic; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 27 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 18Mar2021 10:15 (Lot number: EP6955) at the age of 27 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: SPRINTEC; B12-VITAMIN; CLARITIN. The following information was reported: VACCINATION SITE PAIN (non-serious) with onset 19Mar2021, outcome "recovered", described as "Soreness in left arm"; FATIGUE (non-serious) with onset 19Mar2021, outcome "recovered", described as "Fatigue/needed to sleep and rest"; LETHARGY (non-serious) with onset 19Mar2021, outcome "recovered", described as "lethargic". Therapeutic measures were not taken as a result of vaccination site pain, fatigue, lethargy. Additional information: There were no other vaccine in four weeks. There was no covid prior vaccination and patient was not tested for covid post vaccination.  No follow-up attempts are possible. No further information is expected.
no adverse effects; The patient was administered an expired dose of PNEUMOVAX; This spontaneous report was received from a medical assistant referring to a patient of unknown age.   No information was provided regarding the patient's medical history, concurrent conditions or concomitant medications.   On 21-MAY-2019, the patient was vaccinated with 1 dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) intramuscularly for prophylaxis, lot # N023651 which had expired on 20-05-2019.  No adverse effects were reported.  The outcome of expired product administered and no adverse event was unknown.
Vaccine administered after more than 1 temperature excursion; Vaccine administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031L20A and 031A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 13-Feb-2021 at 12:05 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 20-Mar-2021 at 11:19 AM, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 59.30 for dose administered on 13-Feb-2021 and 59.39 for dose administered on 20-Mar-2021.  Concomitant products were not provided.  On 13-Jan-2021 vials were moved to clinic. On 09-Feb-2021 the vaccines were moved to fridge. On 13-Feb-2021, the vial underwent the excursion on the following timings: at 09 AM temperature was 32. The vaccine beyond use date was reported as 10-Mar-2021.  On 20-Mar-2021 vials were moved to clinic. On 09-Mar-2021 the vaccines were moved to fridge. On 20-Mar-2021, the vial underwent the excursion on the following timings: at 09 AM temperature was 34. The vaccine beyond use date was reported as 08-Apr-2021.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a Fisherbrand traceable temperature monitor at every hour.  The vial was not in a frozen state at the time of vaccine administration. It was reported that, the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021. The health care professional explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 hour and a half approximately, when the temperature data logger registered 34- or 35-degree Fahrenheit. Treatment medications were not reported.   This case was linked to MOD-2022-566976 (Patient Link).